Article Details

Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene

Retrieved on: 2021-01-11 21:22:30

Tags for this article:

Click the tags to see associated articles and topics

Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene. View article details on hiswai:

Excerpt

Tislelizumab is an anti-PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. In pre-clinical studies, binding ...

Article found on: www.globenewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo